Q3 2022 13F Holders as of 9/30/2022
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
98.6M
-
Number of holders
-
57
-
Total 13F shares, excl. options
-
30.4M
-
Shares change
-
+4.47M
-
Total reported value, excl. options
-
$160M
-
Value change
-
+$25M
-
Put/Call ratio
-
0.61
-
Number of buys
-
24
-
Number of sells
-
-38
-
Price
-
$5.28
Significant Holders of ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY) as of Q3 2022
74 filings reported holding SPRY - ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share as of Q3 2022.
ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY) has 57 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 30.4M shares
of 98.6M outstanding shares and own 30.86% of the company stock.
Largest 10 shareholders include ORBIMED ADVISORS LLC (8.74M shares), FMR LLC (4.76M shares), K2 PRINCIPAL FUND, L.P. (3.25M shares), Rubric Capital Management LP (2.7M shares), Nextech Invest AG (1.91M shares), Nantahala Capital Management, LLC (1.25M shares), VANGUARD GROUP INC (1.09M shares), SECTORAL ASSET MANAGEMENT INC (1.05M shares), Woodline Partners LP (813K shares), and BlackRock Inc. (728K shares).
This table shows the top 57 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.